GKOS
Glaukos Corporation
GKOS's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over GKOS overall, supported by stronger fundamentals and lower modeled downside.
GKOS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Healthy | |
| Weak |
GKOS's revenue and cash flow are currently healthy, but its profitability and balance sheet are weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
GKOS PE Valuation
GKOS has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 170x next year's earnings.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
GKOS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect GKOS to return to profit, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
GKOS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.44 | — |
| Q3 2026 | -$2.96 | -$1.46 |
| Q2 2026 | -$3.27 | -$1.66 |
| Q1 2026 | -$3.30 | -$1.03 |
| Q4 2025 | -$3.28 | -$0.51 |
| Q3 2025 | -$1.50 | +$1.46 |
| Q2 2025 | -$1.61 | +$1.59 |
| Q1 2025 | -$2.27 | +$0.61 |
| Q4 2024 | -$2.77 | +$0.01 |
GKOS lost $2.96 per share over the past year, a bigger loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over GKOS on earnings quality, reporting a profit while its opponent remains loss making.
GKOS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $211M | +58% |
| Q2 2026 | $185.6M | +50% |
| Q1 2026 | $150.6M | +41% |
| Q4 2025 | $143.1M | +36% |
| Q3 2025 | $133.5M | +38% |
| Q2 2025 | $124.1M | +30% |
| Q1 2025 | $106.7M | +25% |
| Q4 2024 | $105.5M | +28% |
GKOS's revenue has grown year over year for 15 quarters in a row: $211M last quarter, up 58% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.4% | +13 points |
| Q2 2026 | -9.3% | +9 points |
| Q1 2026 | -13% | +6.2 points |
| Q4 2025 | -98% | -71 points |
| Q3 2025 | -12% | +13 points |
| Q2 2025 | -18% | +13 points |
| Q1 2025 | -19% | +26 points |
| Q4 2024 | -27% | +20 points |
GKOS's operating margin was 0.4% last quarter, up 13 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over GKOS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over GKOS on profitability, with a higher operating margin.
GKOS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $36.5M | +$48.2M |
| Q2 2026 | $12.1M | +108% |
| Q1 2026 | -$16.5M | +$4M |
| Q4 2025 | $3.9M | +$5.2M |
| Q3 2025 | -$11.7M | -$689K |
| Q2 2025 | $5.8M | +$26.3M |
| Q1 2025 | -$20.5M | +$14.4M |
| Q4 2024 | -$1.2M | +$13.7M |
GKOS has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
GKOS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4% | +2.4M shares |
| 1 year | +6.6% | +3.8M shares |
| 3 years | +26% | +12.5M shares |
| 5 years | +24% | +11.9M shares |
| Available history | +49% | +20.1M shares |
GKOS has 61M diluted shares, up 6.6% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over GKOS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
GKOS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | 9.4x | High |
GKOS's net debt is about 9.3 years of its operating earnings (EBITDA).
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
GKOS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.8 | Overbought |
| Stochastic | 84.2 | Overbought |
GKOS's weekly RSI is 75 (overbought) and its Stochastic is 84 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
GKOS PE vs Healthcare Sector
GKOS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
GKOS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $192.0 | 28% above |
| 20 week MA | $177.6 | 39% above |
| 50 week MA | $142.0 | 73% above |
| 100 week MA | $123.5 | 99% above |
| 200 week MA | $106.0 | 132% above |
GKOS is in an uptrend: it's above all five of its weekly moving averages, and 132% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
GKOS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $55.0 | $74.0 | +35% |
| 2021 | $74.0 | $46.8 | -37% |
| 2022 | $46.8 | $42.6 | -8.9% |
| 2023 | $42.6 | $79.5 | +86% |
| 2024 | $79.5 | $151.2 | +90% |
| 2025 | $151.2 | $116.2 | -23% |
| 2026 YTD | $116.2 | $246.0 | +112% |
GKOS has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.